230 related articles for article (PubMed ID: 23757392)
1. Comprehensive genomic profiling in diabetic nephropathy reveals the predominance of proinflammatory pathways.
Kelly KJ; Liu Y; Zhang J; Goswami C; Lin H; Dominguez JH
Physiol Genomics; 2013 Aug; 45(16):710-9. PubMed ID: 23757392
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic Nephropathy.
Gurley SB; Ghosh S; Johnson SA; Azushima K; Sakban RB; George SE; Maeda M; Meyer TW; Coffman TM
Diabetes; 2018 Oct; 67(10):2096-2106. PubMed ID: 30065034
[TBL] [Abstract][Full Text] [Related]
3. Genomic expression profiling and bioinformatics analysis on diabetic nephrology with ginsenoside Rg3.
Wang J; Cui C; Fu L; Xiao Z; Xie N; Liu Y; Yu L; Wang H; Luo B
Mol Med Rep; 2016 Aug; 14(2):1162-72. PubMed ID: 27279428
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy.
Zanchi C; Macconi D; Trionfini P; Tomasoni S; Rottoli D; Locatelli M; Rudnicki M; Vandesompele J; Mestdagh P; Remuzzi G; Benigni A; Zoja C
Diabetologia; 2017 Jun; 60(6):1114-1125. PubMed ID: 28364255
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.
Rayego-Mateos S; Morgado-Pascual JL; Opazo-Ríos L; Guerrero-Hue M; García-Caballero C; Vázquez-Carballo C; Mas S; Sanz AB; Herencia C; Mezzano S; Gómez-Guerrero C; Moreno JA; Egido J
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471207
[TBL] [Abstract][Full Text] [Related]
6. The Role of Chemokines and Chemokine Receptors in Diabetic Nephropathy.
Chang TT; Chen JW
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32365893
[TBL] [Abstract][Full Text] [Related]
7. Expression and cellular distribution of TLR4, MyD88, and NF-κB in diabetic renal tubulointerstitial fibrosis, in vitro and in vivo.
Liu P; Li F; Qiu M; He L
Diabetes Res Clin Pract; 2014 Aug; 105(2):206-16. PubMed ID: 24894085
[TBL] [Abstract][Full Text] [Related]
8. Postischemic inflammatory syndrome: a critical mechanism of progression in diabetic nephropathy.
Kelly KJ; Burford JL; Dominguez JH
Am J Physiol Renal Physiol; 2009 Oct; 297(4):F923-31. PubMed ID: 19656916
[TBL] [Abstract][Full Text] [Related]
9. High resolution molecular and histological analysis of renal disease progression in ZSF1 fa/faCP rats, a model of type 2 diabetic nephropathy.
Dower K; Zhao S; Schlerman FJ; Savary L; Campanholle G; Johnson BG; Xi L; Nguyen V; Zhan Y; Lech MP; Wang J; Nie Q; Karsdal MA; Genovese F; Boucher G; Brown TP; Zhang B; Homer BL; Martinez RV
PLoS One; 2017; 12(7):e0181861. PubMed ID: 28746409
[TBL] [Abstract][Full Text] [Related]
10. Roux-en-Y Esophagojejunostomy Ameliorates Renal Function Through Reduction of Renal Inflammatory and Fibrotic Markers in Diabetic Nephropathy.
Wang C; He B; Piao D; Han P
Obes Surg; 2016 Jul; 26(7):1402-13. PubMed ID: 26510754
[TBL] [Abstract][Full Text] [Related]
11. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential.
Chen HY; Huang XR; Wang W; Li JH; Heuchel RL; Chung AC; Lan HY
Diabetes; 2011 Feb; 60(2):590-601. PubMed ID: 20980457
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel targets of diabetic nephropathy and PEDF peptide treatment using RNA-seq.
Rubin A; Salzberg AC; Imamura Y; Grivitishvilli A; Tombran-Tink J
BMC Genomics; 2016 Nov; 17(1):936. PubMed ID: 27855634
[TBL] [Abstract][Full Text] [Related]
13. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis.
Xiang E; Han B; Zhang Q; Rao W; Wang Z; Chang C; Zhang Y; Tu C; Li C; Wu D
Stem Cell Res Ther; 2020 Aug; 11(1):336. PubMed ID: 32746936
[TBL] [Abstract][Full Text] [Related]
14. Inflammation in diabetic nephropathy.
Lim AK; Tesch GH
Mediators Inflamm; 2012; 2012():146154. PubMed ID: 22969168
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy.
Berthier CC; Zhang H; Schin M; Henger A; Nelson RG; Yee B; Boucherot A; Neusser MA; Cohen CD; Carter-Su C; Argetsinger LS; Rastaldi MP; Brosius FC; Kretzler M
Diabetes; 2009 Feb; 58(2):469-77. PubMed ID: 19017763
[TBL] [Abstract][Full Text] [Related]
16. An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy.
Xiao Y; Liu Y; Lai Z; Huang J; Li C; Zhang Y; Gong X; Deng J; Ye X; Li X
J Ethnopharmacol; 2021 Apr; 270():113806. PubMed ID: 33444721
[TBL] [Abstract][Full Text] [Related]
17. Renal iron overload in rats with diabetic nephropathy.
Dominguez JH; Liu Y; Kelly KJ
Physiol Rep; 2015 Dec; 3(12):. PubMed ID: 26702071
[TBL] [Abstract][Full Text] [Related]
18. Concurrent neprilysin inhibition and renin-angiotensin system modulations prevented diabetic nephropathy.
Malek V; Sharma N; Sankrityayan H; Gaikwad AB
Life Sci; 2019 Mar; 221():159-167. PubMed ID: 30769114
[TBL] [Abstract][Full Text] [Related]
19. Role of heparanase-driven inflammatory cascade in pathogenesis of diabetic nephropathy.
Goldberg R; Rubinstein AM; Gil N; Hermano E; Li JP; van der Vlag J; Atzmon R; Meirovitz A; Elkin M
Diabetes; 2014 Dec; 63(12):4302-13. PubMed ID: 25008182
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy.
Lavoz C; Matus YS; Orejudo M; Carpio JD; Droguett A; Egido J; Mezzano S; Ruiz-Ortega M
Kidney Int; 2019 Jun; 95(6):1418-1432. PubMed ID: 30982673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
